NASDAQ:ENDP - Endo International Stock Price, News, & Analysis

Question 1

What is Endo International's stock symbol?

Answer

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

Question 2

How were Endo International's earnings last quarter?

Answer

Endo International PLC (NASDAQ:ENDP) released its earnings results on Wednesday, August, 8th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.54 by $0.22. The company had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The firm's quarterly revenue was down 18.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.93 EPS. View Endo International's Earnings History.

Question 3

When is Endo International's next earnings date?

Answer

Endo International is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Endo International.

Question 4

What guidance has Endo International issued on next quarter's earnings?

Answer

Endo International updated its FY18 earnings guidance on Wednesday, August, 8th. The company provided earnings per share guidance of $2.50-2.60 for the period, compared to the Thomson Reuters consensus estimate of $2.41. The company issued revenue guidance of $2.75-2.85 billion, compared to the consensus revenue estimate of $2.76 billion.

Question 5

What price target have analysts set for ENDP?

Answer

18 equities research analysts have issued 1 year price objectives for Endo International's stock. Their forecasts range from $7.00 to $26.00. On average, they expect Endo International's share price to reach $14.70 in the next twelve months. This suggests that the stock has a possible downside of 8.8%. View Analyst Price Targets for Endo International.

Question 6

What is the consensus analysts' recommendation for Endo International?

Answer

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 14 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International.

Question 7

What are Wall Street analysts saying about Endo International stock?

Answer

Here are some recent quotes from research analysts about Endo International stock:

1. According to Zacks Investment Research, "Endo is in the process of redefining its business, given the persistent decline in the generic business and withdrawal of opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The focus now is on sterile injectables and Xiaflex. Sales of Xiaflex are being driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Revenues from the sterile injectables business are being driven by the continued growth of Adrenalin. The business is poised to become Endo's core business. While the turnaround might take time, the company seems to be on the right track. Shares have outperformed the industry in the year so far. However, the generic business is expected to face further challenges. Competition is expected to intensify further in 2018." (9/18/2018)
2. Canaccord Genuity analysts commented, "We view Athenex’s compounded vasopressin launch today as more headline risk than an actual financial hit to Endo’s near-term results. We expect Endo to restart litigation with FDA regarding compounding guidance and we’d also expect patent litigation against Athenex that could potentially enjoin sales of the compounded product. While ENDP shares have had strong momentum of late, we remain concerned that little events like these – along with broader opioid and product litigation – could dent that momentum. As such, we maintain our HOLD rating on ENDP shares." (8/13/2018)
3. Cantor Fitzgerald analysts commented, ". We are raising our 12 month PT for ENDP shares to $12 from $7. The increase in our PT is driven by multiple expansion (from 8x to 9x 2019 EV/EBITDA versus 10x for the comps). We think this is deserved since generic drug pricing has stabilized for ENDP, according to the company, and we are optimistic that ENDP could report positive data for CCH to treat cellulite as early as the end of this year versus its official guidance of 2019. The following points support our view." (7/23/2018)
4. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)

Question 8

Are investors shorting Endo International?

Answer

Endo International saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 37,153,175 shares, an increase of 5.6% from the August 15th total of 35,166,960 shares. Based on an average daily trading volume, of 4,151,377 shares, the short-interest ratio is currently 8.9 days. Currently, 18.5% of the shares of the stock are short sold. View Endo International's Current Options Chain.

Question 9

Who are some of Endo International's key competitors?

Answer

Some companies that are related to Endo International include GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Bausch Health Companies (BHC), Valeant Pharmaceuticals (VRX), Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE) and Ionis Pharmaceuticals (IONS).

Question 10

Who are Endo International's key executives?

Answer

Endo International's management team includes the folowing people:

Mr. Paul V. Campanelli, Pres, CEO & Director (Age 56)
Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 61)

Question 11

Who are Endo International's major shareholders?

Answer

Endo International's stock is owned by a number of of institutional and retail investors. Top institutional investors include Connor Clark & Lunn Investment Management Ltd. (1.46%), Bank of New York Mellon Corp (1.09%), Bank of New York Mellon Corp (1.09%), Diamond Hill Capital Management Inc. (0.49%), Nomura Holdings Inc. (0.41%) and Schroder Investment Management Group (0.33%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel and Terrance J Coughlin. View Institutional Ownership Trends for Endo International.

Question 12

Which institutional investors are selling Endo International stock?

Answer

ENDP stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Connor Clark & Lunn Investment Management Ltd., Nomura Holdings Inc., Capital Fund Management S.A., Canada Pension Plan Investment Board, Alps Advisors Inc., Gabelli Funds LLC and Systematic Financial Management LP. View Insider Buying and Selling for Endo International.

Question 13

Which institutional investors are buying Endo International stock?

Answer

ENDP stock was bought by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Schroder Investment Management Group, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Sivik Global Healthcare LLC, Arizona State Retirement System, River & Mercantile Asset Management LLP and Price Capital Management Inc.. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.

Question 14

How do I buy shares of Endo International?

Answer

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 15

What is Endo International's stock price today?

Answer

One share of ENDP stock can currently be purchased for approximately $16.12.

Question 16

How big of a company is Endo International?

Answer

Endo International has a market capitalization of $3.61 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.

Question 17

What is Endo International's official website?

Answer

The official website for Endo International is http://www.endo.com.

Question 18

How can I contact Endo International?

Answer

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		787 (Vote Outperform)
Underperform Votes:		667 (Vote Underperform)
Total Votes:		1,454

NASDAQ:ENDP - Endo International Stock Price, News, & Analysis

Receive ENDP News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Endo International (NASDAQ:ENDP) Frequently Asked Questions